Hanson has 6+ years of consulting experience. He has led gene therapy commercial assessments in >30 unique indications for multiple leading GT companies. He has expertise in early-stage commercial assessments, portfolio strategy and prioritization in metabolic, autoimmune and neurologic disorders. Hanson has helped to lead the development of Trinity’s gene therapy expertise, focusing on early-stage / pre-clinical strategy, NPV modeling, BD due diligence and forecasting.

Hanson has a BS in chemistry from Williams College.